- UroToday Home
- Urologic Oncology
Prostate Cancer Abstracts and Beyond
Recent Abstracts
-
Avenda Health Receives FDA Investigational Device Exemption for AI-enabled Prostate Cancer TherapyProstate CancerAugust 9, 2022
-
Predictors and trends of opioid-sparing radical prostatectomy from a large national cohort.Prostate CancerAugust 9, 2022
-
Satisfaction with Clinician-Led Germline Genetic Counseling in Patients with Prostate Cancer.Prostate CancerAugust 9, 2022
-
The role of multiparametric ultrasound in the detection of clinically significant prostate cancer.Prostate CancerAugust 9, 2022
-
Head-to-head comparison of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies.Prostate CancerAugust 9, 2022
-
A genome-wide CRISPR-Cas9 knockout screen identifies novel PARP inhibitor resistance genes in prostate cancer.Prostate CancerAugust 9, 2022
-
The Low Rate of Adherence to Checklist for Artificial Intelligence in Medical Imaging Criteria Among Published Prostate MRI Artificial Intelligence Algorithms.Prostate CancerAugust 8, 2022
-
18F-Choline PET/CT or PET/MR and the evaluation of response to systemic therapy in prostate cancer: are we ready?Prostate CancerAugust 8, 2022
-
Association Between Prostate-Specific Antigen Screening and Prostate Cancer Mortality Among Non-Hispanic Black and Non-Hispanic White US Veterans.Prostate CancerAugust 8, 2022
-
Genetic Testing and Its Clinical Application in Prostate Cancer Management: Consensus Statements from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology.Prostate CancerAugust 8, 2022
Beyond the Abstracts
-
Changes in Prostate Cancer Survival Among Insured Patients in Relation to USPSTF Screening Recommendations - Beyond the AbstractProstate CancerAugust 9, 2022
-
Real-World Analysis of Apalutamide-Associated Skin Adverse Events in Japanese Patients with Advanced Prostate Cancer: A Multi-Institutional Study in the Chu-Shikoku Japan Urological Consortium - Beyond the AbstractProstate CancerAugust 4, 2022
-
Magnetic Resonance Imaging and Targeted Biopsies Compared to Transperineal Mapping Biopsies Before Focal Ablation in Localised and Metastatic Recurrent Prostate Cancer after Radiotherapy - Beyond the AbstractProstate CancerJuly 28, 2022
-
Real-World Prostate-Specific Antigen Response and Treatment Adherence of Apalutamide in Patients with Non-Metastatic Castration-Resistant Prostate Cancer - Beyond the AbstractProstate CancerJuly 28, 2022
-
Pan-Segmental Intraprostatic Lesions Involving Mid-Gland and Apex of Prostate (Mid-Apical Lesions): Assessing the True Value of Extreme Apical Biopsy Cores - Beyond the AbstractProstate CancerJuly 25, 2022
-
Diagnostic and Prognostic Factors in Patients with Prostate Cancer: A Systematic Review - Beyond the AbstractProstate CancerJuly 20, 2022
-
Inherited Risk Assessment and Its Clinical Utility for Predicting Prostate Cancer from Diagnostic Prostate Biopsies - Beyond the AbstractProstate CancerJuly 19, 2022
-
Association of Patient and Imaging-Related Factors with False Negative MRI-Targeted Prostate Biopsies of Suspicious PI-RADS 4 and 5 Lesions - Beyond the AbstractProstate CancerJuly 14, 2022
-
Real-World Effectiveness of Sipuleucel T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor–targeting Agents - Beyond the AbstractProstate CancerJuly 13, 2022
-
Epidemiology of Urological Cancers in Brazil: Trends in Mortality Rates Over More Than Two Decades - Beyond the AbstractProstate CancerJuly 12, 2022
